ArticleJournal of medical biochemistry2025

Combination of prostate cancer antigen 3 (PCA3), sarcosine, glypican-1 (GPC1), urokinase plasminogen activator receptor (uPAR), and thymidine kinase 1 (TK1), and T2WI and DWI radiomics model for distinguishing benign prostatic hyperplasia, prostate cancer, and prostatitis.

Fan Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.